Vasoactive intestinal peptide-induced prolactin release in hypothyroid patients

Abstract

VIP is an established prolactin-releasing factor. VIP gene expression at the anterior pituitary level and the central nervous system is regulated by thyroid hormones. On the other hand, primary hypothyroidism leads in many cases to amenorrhea, galactorrhea and hyperprolactinemia. In this study we assessed prolactin responses to VIP (75 μg iv infusion over 12 min) in a group of six hypothyroid women (mean age±SE, 38.8±3.3 yr; serum TSH levels, mU/L, 116.3±23.9), before treatment and after normalization of thyroid hormone levels during thyroxine (T4) replacement therapy (100–150 μg/day over 12–16 weeks). Furthermore, we assessed if VIP infusion had any effects on serum GH levels in these patients. In hypothyroid women, VIP infusion increased serum prolactin concentrations with peak levels being attained at 15 min (28.8±3.4 μg/L). The Area Under the Curve (AUC) was 1921±103 μg/L/2h. PRL responses to VIP were unchanged after T4 therapy, both in terms of peak levels (28.7±2.2 μg/L, NS) and of AUC (2079±261 μg/L72h, NS). Serum GH levels were unaffected by VIP administration. In conclusion our study shows that, in hypothyroid patients, restoration of normal thyroid hormone levels by thyroxine replacement therapy does not affect lactotroph responsiveness to VIP. Therefore, our data do not support the hypothesis that VIP might contribute to the hypothyroid-induced hyperprolactinemia seen in man.